cytomegalovirus disease

Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to cytomegalovirus disease: CMV


 (CMV) [si″to-meg´ah-lo-vi″rus]
any of a subfamily of host-specific herpesviruses infecting humans, monkeys, and rodents, producing unique large cells with inclusion bodies. Opportunistic infection with this virus is common in immunocompromised individuals, causing clinical illnesses such as cytomegalovirus retinitis, pneumonia, esophagitis, colitis, adrenalitis, and hepatitis. It can also cause cytomegalic inclusion disease, a variety of gastrointestinal infections, and encephalitis. Most infections are mild in immunocompetent persons, but it has been associated with a syndrome called cytomegalovirus mononucleosis.
cytomegalovirus disease cytomegalic inclusion disease.

cy·to·meg·a·lic in·clu·sion dis·ease

caused by cytomegalovirus, a member of the Herpesviridae family; the presence of inclusion bodies within the cytoplasm and nuclei of enlarged cells of various organs of newborn infants dying with jaundice, hepatomegaly, splenomegaly, purpura, thrombocytopenia, and fever; the condition also occurs, at all ages, as a complication of other diseases in which immune mechanisms are severely depressed, and has been found incidentally in salivary gland epithelium, apparently as a localized or mild infection (salivary gland virus disease).

cytomegalovirus disease

References in periodicals archive ?
The effect of cytomegalovirus antigenemia titer on the efficacy of preemptive therapy for the prevention of cytomegalovirus disease after kidney transplantation.
Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation.
Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients.
Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation.
Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation.
Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant.
Comparision between RFLP-PCR and antigenemia for pp65 antigen for diagnosis of cytomegalovirus disease after kidney transplantation.
Among their perspectives are inhibiting HIV entry, helicase-primase inhibitors as a new approach to combating herpes simplex virus and varicella zoster virus, alkoxyalkyl ester pro-drugs of antiviral nucleoside phosphate and phosphonates, maribavir as a novel benzimidazole ribonucleoside for preventing and treating cytomegalovirus diseases, lethal mutagenesis as an unconventional approach to combating HIV, silencing viruses with antiviral RNAi, and neuraminidase inhibitors as anti-influenza agents.

Full browser ?